What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CBT & Strata Oncology Enter Development Deal

To drive patient enrollment in CBT’s ongoing Phase 1/2 trial of CBT-101 in patients with c-Met dysregulated malignancies including non-small cell lung cancer

CBT Pharmaceuticals and Strata Oncology have entered into an agreement to drive patient enrollment in CBT’s ongoing Phase 1/2 trial of CBT-101 in cancer patients with c-Met dysregulated malignancies including non-small cell lung cancer. 

 
Under the terms of the agreement, Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT’s clinical development program for CBT-101.

“Partnerships with innovative pharmaceutical companies like CBT, who share our vision for biomarker-driven drug development, are essential to our mission to accelerate development of promising precision therapies for cancer patients,” said Dan Rhodes, Ph.D., chief executive officer of Strata Oncology. “This marks the eighth study in Strata’s portfolio of pharma-sponsored precision trials which are available to eligible advanced cancer patients at our partner health systems.”

The Strata Trial is a genomic screening protocol providing comprehensive tumor molecular profiling to advanced cancer patients at no cost, and proactive enrollment support for a portfolio of pharma-sponsored precision therapy trials. Tumor profiling through the Strata Trial is provided as part of routine care to solid tumor patients across the Strata Precision Oncology Network, a network of 14 leading health systems representing more than 100,000 new cancer patients annually. This large network of trial-ready health systems with fully pre-screened advanced cancer populations enables rapid and predictable enrollment of precision therapy trials.

Gavin Choy, chief operating officer of CBT Pharmaceuticals, said, “One of our goals at CBT is to develop selective medicines in cancer populations driven by a particular mutation. By partnering with Strata’s extensive oncology network and genomic screening capabilities, we can accelerate the development of CBT-101 by broadening patient access to our investigational therapy and targeting the patients who may derive the most benefit.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics